Semaglutide (brand-name, Novo Nordisk)
Compounded medications are prepared by state-licensed pharmacies. Prescription only — available if a licensed provider determines treatment is appropriate after your online visit. Not available in all states.
No insurance, no membership fees, no auto-renewal. Reorder when you're ready.
Semaglutide is a GLP-1 receptor agonist that slows stomach emptying, reduces appetite and food noise and improves insulin release after meals, so you eat less without constant hunger. In the 68-week STEP 1 trial, adults on Wegovy® 2.4 mg lost an average of about 15% of their body weight with lifestyle changes, versus about 2.5% on placebo. In the SELECT trial it reduced major cardiovascular events by 20% in adults with established heart disease.
Wegovy® contains the same molecule as Ozempic® (approved for type 2 diabetes) and is the reference product for compounded semaglutide.
Wegovy® follows a 16-week ramp: 0.25 mg once weekly for four weeks, then 0.5 mg, 1 mg, 1.7 mg and finally the 2.4 mg maintenance dose, each for four weeks. Your provider may hold a step longer if you need time to adjust. Each pen is one dose; a monthly plan is four pens at the strength your provider prescribes, priced the same at every strength.
Inject under the skin of the abdomen, thigh or upper arm on the same day each week. Keep pens refrigerated; an unopened pen can sit at room temperature for up to 28 days.
Wegovy® is prescribed to adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, and to adults with established cardiovascular disease and excess weight who want to lower their risk of heart attack and stroke. It's the right choice for people who prefer or require the FDA-approved product, who are continuing a Wegovy® prescription without coverage, or who want pre-filled pens instead of a vial.
It is not for anyone who is pregnant, breastfeeding or planning a pregnancy, for people with type 1 diabetes, or for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. GobyMeds prescribes to adults only.
Month 1 (0.25 mg). The starting dose is for tolerability. Appetite begins to ease; any nausea is usually mild and short-lived.
Months 2–4 (0.5–1.7 mg). Each monthly step strengthens the effect on hunger and cravings and weight loss becomes steady.
Month 5 onward (2.4 mg). You reach the maintenance dose. Most people see clear changes in weight, waist size and energy, and blood pressure and blood sugar often improve.
Beyond 6 months. Weight loss continues gradually toward a plateau; the trial ran 68 weeks. Your provider will plan maintenance with you.
Answers from the GobyMeds care team. Still have a question? Your provider can answer it during your online visit.
Wegovy® (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults and adolescents 12 and older with obesity, or adults with overweight and a weight-related condition, alongside diet and exercise. It is also approved to reduce the risk of major cardiovascular events in adults with established heart disease and obesity or overweight. GobyMeds prescribes it to adults only.
Wegovy® follows a 16-week ramp: 0.25 mg weekly for four weeks, then 0.5 mg, 1 mg, 1.7 mg and finally the 2.4 mg maintenance dose, each for four weeks. Your provider may hold a step longer if you need more time to adjust. Each plan is one month of single-dose pens at your prescribed strength, priced the same at every strength.
Wegovy® is the FDA-approved product manufactured by Novo Nordisk in pre-filled single-dose pens. Compounded semaglutide uses the same active ingredient but is prepared by a compounding pharmacy as a multi-dose vial at a much lower price and is not FDA-approved. GobyMeds is not affiliated with Novo Nordisk.
Brand-name pens are manufactured by the original pharmaceutical company, FDA-approved and sold at the manufacturer's list price; GobyMeds adds no markup beyond the pharmacy's cost and the included provider visit. Compounded versions are prepared by licensed pharmacies for individual prescriptions and cost considerably less, but they are not FDA-approved. Your provider can discuss which option fits your situation.
GobyMeds does not bill insurance, and manufacturer savings cards generally can't be applied to a cash-pay telehealth order. If you have coverage for this medication, your own physician and in-network pharmacy are usually the lower-cost route; we're a good fit when coverage is denied or unavailable and you want a fast, transparent cash price. HSA and FSA cards are accepted.
Supply of brand-name GLP-1 pens has fluctuated over the past few years. We show current availability on this page and confirm it again before your order is sent to the pharmacy. If a strength is temporarily unavailable, your provider may suggest an alternative strength, a short bridge on compounded medication, or waiting for restock, and you'll never be charged for medication that can't be shipped.
Pens ship refrigerated from a licensed U.S. pharmacy in insulated cold-chain packaging with a signature typically required on delivery. Most orders arrive within two to five business days of approval. Refrigerate pens on arrival; an unopened pen can be kept at room temperature for up to 21 days (Zepbound®) or 28 days (Wegovy®) if needed.
If a GobyMeds provider decides a prescription isn't appropriate for you, you receive a 100% refund of the medication price (lab fees, where they apply, are not refunded). Once your order has been sent to our medical partners or to the pharmacy for fulfillment we will do our best to accommodate changes or cancellations, but we can't guarantee them, and in some cases an adjustment or cancellation carries a $50 medical consultation fee.
Because of regulations covering prescription medication, we are unable to accept returned medication for a refund.
No insurance is needed and GobyMeds does not bill insurance. The price you see is the price you pay, with provider consultation and shipping included and no membership fee.
HSA and FSA cards are accepted at checkout, and we can provide a letter of medical necessity if your plan administrator asks for one.
You answer a short health questionnaire and upload a photo ID. A licensed U.S. provider reviews your history, confirms the treatment is appropriate, and writes the prescription. There is no video call to schedule unless your provider or your state requires one, and follow-up messaging with your care team is included with every plan.
If you're not a candidate, you'll be told why and refunded in full.
Brand-name semaglutide (Wegovy®) pens, prescribed online when clinically appropriate. GobyMeds is not affiliated with Novo Nordisk.
Start your online visitCommon side effects are nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, indigestion, dizziness, bloating, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu and heartburn, mostly during dose increases. Serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, increased heart rate, diabetic retinopathy complications, severe allergic reactions and depression or suicidal thoughts.
Wegovy® carries a boxed warning for thyroid C-cell tumors observed in rodents. Seek care for severe abdominal pain, a neck lump, hoarseness or trouble swallowing. Full prescribing information is available from Novo Nordisk; report side effects to the FDA at 1-800-FDA-1088.
Do not use Wegovy® if you or a family member has had medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, if you have had a serious allergic reaction to semaglutide, or if you are pregnant, breastfeeding or planning a pregnancy (stop at least two months before trying to conceive). Do not combine with another GLP-1 medication. Tell your provider about pancreatitis, gallbladder, kidney or eye disease, depression, and all medications you take, including insulin or sulfonylureas. Prescription only; available only when a licensed provider determines it is appropriate. Not available in all states. Wegovy® is a registered trademark of Novo Nordisk A/S; GobyMeds is not affiliated with Novo Nordisk.
This page is for informational purposes and does not replace a consultation with a licensed provider. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. Brand names are trademarks of their respective owners; GobyMeds is not affiliated with them.
.svg)
